Clinical guideline
Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline
CA Cancer J Clin · 2026
Studies and guidelines: Cervical cancer
27 items with a structured summary · Cervical cancer: the complete guide
Clinical guideline
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
J Natl Compr Canc Netw · 2025
Clinical guideline
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
Int J Gynecol Cancer · 2023
Clinical guideline
Revised FIGO staging for carcinoma of the cervix uteri
Intl J Gynecology & Obste · 2019
Measurement of lateral extension removedStage IA
Clinical guideline
Screening for Cervical Cancer
JAMA · 2018
Decrease from 2.8 to 2.3 deaths per 100,000 womenTrend in cervical cancer mortality in the United States (2000 to 2015)
Clinical guideline
Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society
CA A Cancer J Clinicians · 2020
25 years (vs 21 years in the 2012 recommendations)Age to start screening
Clinical trial · Phase 3
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial
JAMA Oncol · 2026
28.6 vs 16.5 monthsMedian overall survival (PD-L1 CPS ≥1)
Clinical trial · Phase 3
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
Lancet · 2024
72% vs 64%5-year progression-free survival
Clinical trial · Phase 3
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet · 2024
82.6% vs 74.8%36-month overall survival
Clinical trial · Phase 3
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
N Engl J Med · 2024
2.52% (simple) vs 2.17% (radical)3-year pelvic recurrence
Clinical trial · Phase 3
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
JCO · 2023
28.6 vs 16.5 monthsMedian overall survival — CPS ≥1 population (548 patients)
Clinical trial
Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women
NEJM Evidence · 2022
38 cases: one in each of the bivalent and 9-valent groups and 36 in the meningococcal groupNumber of new persistent HPV 16/18 infections (mITT group)
Observational study
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study
The Lancet · 2021
34%Relative reduction in cervical cancer — vaccine offered at age 16 to 18 years
Observational study
HPV Vaccination and the Risk of Invasive Cervical Cancer
N Engl J Med · 2020
19 cases in vaccinated vs 538 cases in unvaccinatedNumber of cervical cancer cases
Other
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
The Lancet · 2020
Reduced from 19.8 (range 19.4–19.8) to 2.1 (2.0–2.6) cases per 100,000 woman-yearsAge-standardised cervical cancer incidence with vaccination of girls only (over the next century)
Other
Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries
The Lancet · 2020
13.2 (range 12.9 to 14.1) per 100,000 womenCervical cancer mortality rate in the 78 countries in 2020
Review article
Cervical cancer
The Lancet · 2019
More than half a millionNumber of women affected each year
Clinical trial · Phase 2
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
J Clin Oncol · 2019
12.2%Objective response (all patients)
Meta-analysis
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses
BMJ · 2018
Pooled ratio 0.99Sensitivity of PCR-based tests on self-samples vs clinician samples (CIN2+ or CIN3+)
Clinical trial · Phase 3
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
N Engl J Med · 2018
86.0% vs 96.5%4.5-year disease-free survival
Clinical trial · Phase 3
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Lancet · 2017
16.8 vs 13.3 monthsMedian overall survival
Meta-analysis
Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials
The Lancet · 2014
0.60 (95% CI 0.40–0.89)Rate ratio for invasive cervical carcinoma in all women (from entry to end of follow-up)
Clinical trial
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
N Engl J Med · 1999
Relative risk of progression or death 0.57 (95% CI 0.42–0.78)Progression-free survival: group 1 (cisplatin) vs group 3 (hydroxyurea)
Clinical trial · Phase 3
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Lancet · 2024
13.7 vs 10.4 monthsMedian progression-free survival
Clinical trial · Phase 3
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
N Engl J Med · 2024
11.5 vs 9.5 monthsMedian overall survival
Clinical trial · Phase 3
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
N Engl J Med · 2021
10.4 vs 8.2 monthsMedian PFS (CPS ≥1)
Clinical trial · Phase 3
Improved survival with bevacizumab in advanced cervical cancer
N Engl J Med · 2014
17.0 vs 13.3 monthsMedian overall survival (with/without bevacizumab)
Nothing found.